The Sputnik V COVID-19 vaccine could be more efficacious than those from AstraZeneca (LON:AZN) or Johnson & Johnson (NYSE:JNJ) based on interim trial results.
The two-dose Sputnik vaccine was 91.6% effective at preventing symptomatic COVID-19 and 100% effective at preventing severe and moderate disease in a study involving 19,866 participants.
The data were published in The Lancet. No data, however, was available on the impact of SARS-CoV-2 variants on the vaccine’s efficacy.
Get the full story from our sister, Drug Discovery & Development.